A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Public ClinicalTrials.gov record NCT02087917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine the efficacy of HS-25 (5, 10, 20 or 30 mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 4-week period of treatment in adults with primary hypercholesterolemia.
Study identification
- NCT ID
- NCT02087917
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 376 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2014
- Primary completion
- Aug 31, 2014
- Completion
- Nov 30, 2014
- Last update posted
- Jan 5, 2015
2014
United States locations
- U.S. sites
- 27
- U.S. states
- 20
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Chandler | Arizona | 85224 | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | West Hills | California | — | — |
| Not listed | Doral | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | South Miami | Florida | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Evansville | Indiana | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Overland Park | Kansas | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Auburn | Maine | — | — |
| Not listed | Bethesda | Maryland | — | — |
| Not listed | Methuen | Massachusetts | — | — |
| Not listed | Trenton | New Jersey | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Penndel | Pennsylvania | — | — |
| Not listed | Greensboro | South Carolina | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Norfolk | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02087917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2015 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02087917 live on ClinicalTrials.gov.